The outcome of the first 100 nasopharyngeal cancer patients in Thailand treated by Helical Tomotherapy
Abstract
pURPOSE: To analyze of two-year loco-regional failure free survival (LRFFS), distant metastasis free survival (DMFS), overall survival (OS), and toxicity outcomes of the first 100 nasopharyngeal carcinoma (NPC) patients in Thailand treated by Helical Tomotherapy (HT). MATERIALS AND METHODS: Between March 2012 and December 2015, 100 patients with non-metastatic NPC were treated by HT. All patients treated by platinum-based concurrent chemoradiotherapy (CCRT) and adjuvant or neo-adjuvant chemotherapy. RESULTS: The median age was 51 years (IQR: 42.5- 57.0). The mean ± SD of D95% of PTV70, 59.4 and 54 were 70.2 ± 0.5, 59.8 ± 0.6, and 54.3 ± 0.8, respectively. The mean ± SD of conformity index (CI), and homogeneity index (HI) were 0.89 ± 0.13 and 0.06 ± 0.07. Mean ± SD of D2 % of spinal cord and brainstem were 34.1 ± 4.4 and 53.3 ±6.3 Gy. Mean ± SD of D50 of contralateral and ipsilateral parotid gland were 28.4 ± 6.7 and 38.5 ± 11.2 Gy. At a median follow-up of 33 months (IQR: 25-41), the 2-year LRFFS, DMFS, OS were 94% (95%CI: 87- 98%), 96% (95%CI: 89-98%), and 99% (95%CI: 93-100%), respectively. Acute grade 3 dermatitis, pharyngoesophagitis, and mucositis occurred in 5%, 51%, and 37%, respectively. Late pharyngoesophagitis grade 0 and 1 were found in 98% and 2% of patients. Late xerostomia grade 0, 1 and 2 were found in 17%, 78% and 5%, respectively. CONCLUSIONS: HT offers good dosimetric performance and achieves excellent treatment outcome in NPC patients.
Downloads
Additional Files
Published
How to Cite
Issue
Section
License
License to Publish
Please read the terms of this agreement, print, initial page 1, sign page 3, scan and send the document as one file attached to an e-mail to gsersa@onko-i.si